Save your place

Sign in to WhoBought

Please try again later.

Invesco's Akebia Therapeutics, Inc. (AKBA) position

Yes: as of Q1 2026, Invesco holds 720K shares of AKBA worth $1.0M (0.0% of the disclosed portfolio). Held since at least Q1 2021; that opening coverage snapshot is not counted as a purchase.
View full portfolio →
Current value
$1.0M
Shares held
720K
% of portfolio
0.0%
Est. average buy price (i)
$2.04
est. since Q4 2025
Quarter-end price
$1.39

Estimated trade prices

Average price in quarters with purchases
$3.12
Average prices in quarters with sales
  • Q3 2024: $1.34 (10K shares sold)
  • Q1 2024: $1.60 (3K shares sold)
  • Q3 2023: $1.28 (8K shares sold)
  • Q4 2022: $0.31 (5K shares sold)
  • Q3 2022: $0.39 (14K shares sold)
  • Q2 2022: $0.42 (15K shares sold)
  • Q4 2021: $2.73 (12K shares sold)

AKBA price vs Invesco's position

Dates
$0.8$2$4202420252026Sold 8K shares (25.6%) · Q3 2023. Average closing price $1.28 · Price range $0.87–$1.848KsharessoldAdded 5K shares (22.5%) · Q4 2023. Average closing price $1.02 · Price range $0.80–$1.285KsharespurchasedSold 3K shares (11.4%) · Q1 2024. Average closing price $1.60 · Price range $1.27–$2.243KsharessoldAdded 104K shares (402.4%) · Q2 2024. Average closing price $1.24 · Price range $0.86–$1.63104KsharespurchasedSold 10K shares (7.7%) · Q3 2024. Average closing price $1.34 · Price range $0.94–$1.5510KsharessoldAdded 872 shares (0.7%) · Q4 2024. Average closing price $1.74 · Price range $1.28–$2.13872sharespurchasedAdded 122K shares (46.7%) · Q2 2025. Average closing price $2.75 · Price range $1.55–$3.97122KsharespurchasedAdded 2.0M shares (528.1%) · Q3 2025. Average closing price $3.33 · Price range $2.71–$4.012.0MsharespurchasedAdded 51K shares (7.6%) · Q1 2026. Average closing price $1.37 · Price range $1.18–$1.5551Ksharespurchased← Earlier —3 purchases, 4 sells
Average closing price · filing quarter
$1.37
Price range · filing quarter
$1.18 – $1.55

Every quarterly change

Quarter Action Shares change Est. value change Δ Own Shares held Filing date
Q1 2026 Added +51K +$70K +7.6% 720K May 12, 2026
Q4 2025 First covered 669K Feb 19, 2026
Q3 2025 Added +2.0M +$6.7M +528.1% 2.4M Nov 13, 2025
Q2 2025 Added +122K +$334K +46.7% 382K Aug 13, 2025
Q1 2025 First covered 261K May 12, 2025
Q4 2024 Added +872 +$2K +0.7% 121K Feb 13, 2025
Q3 2024 Reduced −10K −$13K −7.7% 120K Nov 12, 2024
Q2 2024 Added +104K +$128K +402.4% 130K Aug 13, 2024
Q1 2024 Reduced −3K −$5K −11.4% 26K May 14, 2024
Q4 2023 Added +5K +$5K +22.5% 29K Feb 13, 2024
Q3 2023 Reduced −8K −$10K −25.6% 24K Nov 13, 2023
Q2 2023 New +32K +$31K 32K Aug 11, 2023
Q4 2022 Reduced −5K −$2K −2.0% 246K Feb 13, 2023
Q3 2022 Reduced −14K −$6K −5.3% 251K Nov 14, 2022
Q2 2022 Reduced −15K −$6K −5.5% 265K Aug 15, 2022
Q1 2022 First covered 280K May 16, 2022
Q4 2021 Reduced −12K −$33K −5.9% 190K Feb 14, 2022
Q3 2021 Added +15K +$43K +8.1% 202K Nov 15, 2021
Q2 2021 Added +26K +$88K +16.2% 187K Aug 17, 2021
Q1 2021 First covered 161K May 17, 2021
Data through Q1 2026 · filed May 12, 2026
20 grouped rows from 20 quarters

More Invesco positions

Common questions

Does Invesco own AKBA?

Yes. As of Q1 2026, Invesco disclosed 720K shares of AKBA, worth $1.0M. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

When did Invesco buy AKBA?

Invesco held AKBA since at least Q1 2021, when this filing coverage begins; the opening snapshot is not a disclosed purchase. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

Did Invesco sell AKBA?

The quarter-by-quarter table above shows each sale and reduction Invesco disclosed in AKBA. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How many shares of AKBA does Invesco own?

Invesco disclosed 720K shares of AKBA as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

What price did Invesco pay for AKBA?

Invesco began building the AKBA position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How are the estimated trade prices calculated?

13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.